---
schema_version: "secwatch.filing_event.v1"
accession: "0001764046-26-000018"
form_type: "8-K"
ticker: "CLVT"
cik: "0001764046"
company_name: "CLARIVATE PLC"
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:51:10.455127+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Clarivate Q4 revenue $617M, down 7%; pursues LS&H sale; FY26 FCF ~$400M

## Summary
- Q4 net income $3.1M vs loss $191.8M; adjusted EPS $0.20 vs $0.21. Full-year adjusted EBITDA $1,001.8M.
- Organic ACV grew 1.8% in FY2025; recurring revenue mix improved to 88% of total revenue.
- Pursuing sale of Life Sciences & Healthcare; retained Morgan Stanley; proceeds to reduce leverage.
- FY2026 outlook: Adj. EBITDA growth with ~200 bps margin expansion; FCF ~$400M at midpoint.
- Returned $225M to shareholders via share repurchases in 2025 (56M shares).

## SEC filing metadata
- accession: 0001764046-26-000018
- form_type: 8-K
- ticker: CLVT
- cik: 0001764046
- company_name: CLARIVATE PLC
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764046/000176404626000018/0001764046-26-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764046/000176404626000018/clvt-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764046-26-000018
- JSON: https://secwatch.observer/filing/0001764046-26-000018.json
- Plain text: https://secwatch.observer/filing/0001764046-26-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.